8-K: Intuitive Surgical Posts Strong Q3 Growth, Da Vinci 5 Adoption Soars

Intuitive Surgical reported robust third-quarter 2025 financial results, driven by significant procedure growth and increased adoption of its da Vinci and Ion surgical systems.

Summary

• Worldwide procedures (da Vinci and Ion combined) increased by approximately 20% compared with the third quarter of 2024.
• Revenue for Q3 2025 reached $2.51 billion, a 23% increase from $2.04 billion in Q3 2024.
• GAAP net income attributable to Intuitive was $704 million, or $1.95 per diluted share, up from $565 million, or $1.56 per diluted share, in Q3 2024.
• Non-GAAP net income attributable to Intuitive was $867 million, or $2.40 per diluted share, compared to $669 million, or $1.84 per diluted share, in Q3 2024.
• The company placed 427 da Vinci surgical systems, including 240 da Vinci 5 systems, compared to 379 total systems and 110 da Vinci 5 systems in Q3 2024.
• The da Vinci surgical system installed base grew 13% to 10,763 systems, and the Ion endoluminal system installed base grew 30% to 954 systems.
• Repurchased 4.0 million shares of common stock for $1.92 billion during the quarter.

Sentiment

Score: 9

Explanation: The company reported exceptionally strong financial results with significant growth across key metrics including revenue, net income, and procedure volumes. The continued adoption of its advanced surgical systems and expansion of its installed base are highly positive indicators, despite some headwinds from tariffs and increased operating expenses in the outlook.

Positives

• Worldwide procedures grew approximately 20% year-over-year, indicating strong market penetration and utilization.
• Da Vinci procedures increased by approximately 19%, and Ion procedures surged by approximately 52%.
• Total revenue rose 23% to $2.51 billion in Q3 2025, demonstrating robust top-line growth.
• GAAP net income increased to $704 million ($1.95 per diluted share) from $565 million ($1.56 per diluted share) in Q3 2024.
• Non-GAAP net income grew to $867 million ($2.40 per diluted share) from $669 million ($1.84 per diluted share) in Q3 2024.
• Da Vinci surgical system placements increased to 427 from 379 in Q3 2024, with a significant rise in da Vinci 5 system placements (240 vs. 110).
• The installed base for da Vinci systems expanded by 13% to 10,763, and for Ion systems by 30% to 954.
• Instruments and accessories revenue increased by 20% to $1.52 billion, driven by procedure volume growth.
• The company repurchased $1.92 billion of its common stock, signaling confidence in its valuation.

Negatives

• Ion endoluminal system placements decreased to 50 in Q3 2025 from 58 in Q3 2024.
• Cash, cash equivalents, and investments decreased by $1.10 billion during the quarter to $8.43 billion, primarily due to share repurchases and capital expenditures.
• The 2025 full-year outlook for non-GAAP gross profit margin is projected to be 67% to 67.5%, a decrease from 69.1% in 2024, partly due to tariff impacts.
• Non-GAAP operating expense growth is expected to increase to 11% to 13% in 2025, compared to 10% in 2024.

Risks

• Overall macroeconomic environment, including customer spending, costs, tariffs, inflation, and interest rates.
• Geopolitical conflicts, specifically mentioning Ukraine-Russia and the Middle East.
• Disruptions to the supply chain, including difficulties in obtaining sufficient materials.
• Curtailed or delayed capital spending by hospitals.
• Impact of global and regional economic and credit market conditions on healthcare spending.
• Delays in obtaining new product approvals, clearances, or certifications from regulatory authorities like the U.S. Food and Drug Administration (FDA).
• Inability to comply with complex FDA and other regulations, potentially leading to significant enforcement actions.
• Healthcare reform legislation in the U.S. and its impact on hospital spending, reimbursement, and medical device revenues.
• Changes in hospital admissions and actions by payers to limit or manage surgical procedures.
• Uncertainty regarding the timing and success of product development and customer acceptance.
• Risks associated with collaborations, in-licensing arrangements, joint ventures (e.g., with Shanghai Fosun Pharmaceutical), strategic alliances, or partnerships.
• Challenges in completing and successfully integrating acquisitions.
• Intellectual property positions and potential litigation.
• Risks associated with operations and expansion outside of the U.S.
• Unanticipated manufacturing disruptions or inability to meet product demand.
• Reliance on soleand single-sourced suppliers.
• Results of legal proceedings to which the company is or may become a party.
• Adverse publicity regarding the company, product safety, and adequacy of training.
• Impact of changes to tax legislation, guidance, and interpretations.
• Changes in tariffs, trade barriers, and regulatory requirements, including tariffs on imports from Mexico, Germany, and China.

Future Outlook

Intuitive Surgical projects worldwide da Vinci procedure growth of approximately 17% to 17.5% for the full year 2025. The non-GAAP gross profit margin is expected to be between 67% and 67.5% of revenue, a slight decrease from 69.1% in 2024, partly due to an estimated 0.7% impact from tariffs. Non-GAAP operating expense growth is anticipated to be 11% to 13% in 2025, up from 10% in 2024. The company acknowledges potential material impacts from future tariff changes.

Management Comments

• We're pleased with our strong results this quarter, underscored by continued growth in customer use and adoption of our Ion and da Vinci platforms, including da Vinci 5.
• We remain focused on helping our customers achieve the Quintuple Aim: delivering better patient care, improving patient and care team experiences, expanding access to high quality care, and reducing overall care costs.

Industry Context

Intuitive Surgical's strong performance in Q3 2025, particularly the significant growth in da Vinci and Ion procedures and the increased adoption of the da Vinci 5 system, reinforces its leadership position in the robotic-assisted surgery market. The continued expansion of its installed base suggests a deepening entrenchment within healthcare systems globally. While the outlook for gross profit margin reflects broader industry challenges like tariffs and rising operating costs, the robust procedure growth indicates sustained demand for advanced minimally invasive surgical technologies, aligning with the broader trend towards less invasive patient care and efficiency in healthcare delivery.

Legal Proceedings

• Litigation charges are excluded from non-GAAP income from operations, indicating ongoing or potential legal matters.
• Risks include 'results of legal proceedings to which the Company is or may become a party.'

Related Party Transactions

• The joint venture with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is mentioned in the context of risks and non-GAAP adjustments for long-term incentive plan expenses and noncontrolling interest.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased profitability, and a significant share repurchase program.
• Customers (Hospitals/Healthcare Providers): Continued benefit from advanced robotic-assisted surgical systems (da Vinci and Ion) for minimally invasive care, aligning with the 'Quintuple Aim' of better patient care, improved experiences, expanded access, and reduced costs.
• Employees: Share-based compensation is a significant recurring expense, indicating a component of employee remuneration.
• Suppliers: The company's reliance on soleand single-sourced suppliers presents a risk to supply chain stability.

Next Steps

• Hold a teleconference on October 21, 2025, at 1:30 p.m. PDT to discuss the third quarter 2025 financial results.
• Make the webcast replay of the call available on the company's website for at least 30 days.

Key Dates

Recommendation

Intuitive Surgical's Q3 2025 results demonstrate exceptional operational and financial strength, with robust double-digit growth in procedures, revenue, and profitability. The accelerating adoption of the da Vinci 5 system and the expanding installed base for both da Vinci and Ion platforms underscore the company's dominant market position and innovation leadership. While the outlook includes a slight compression in gross profit margin due to tariffs and increased operating expenses, these are manageable headwinds given the underlying demand and growth trajectory. The significant share repurchase program further signals strong management confidence. The company continues to execute effectively in a high-growth, high-margin segment of the healthcare industry, making it a compelling investment.

Keywords

Intuitive Surgical, ISRG, Robotic Surgery, Minimally Invasive Care, da Vinci Surgical System, Ion Endoluminal System, Q3 2025 Earnings, Financial Results, Medical Devices, Healthcare Technology, Procedure Growth, Installed Base, Revenue Growth, GAAP Net Income, Non-GAAP Net Income, Share Repurchase, Surgical Systems, FDA, Tariffs